Compare Cytokinetics Inc (CYTK) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Intel Corp — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Intel Corp trades at $109.08 (market cap $597.96B). The key difference: Intel Corp is far larger — about 70.3× Cytokinetics Inc's market cap, and Intel Corp pays a 2.24% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Intel Corp for 116 Days on average.
| CYTK | INTC | |
|---|---|---|
Market Cap | $8.50B | $597.96B |
Volume | 2,395,556 | 82,330,296 |
Sector | Health | Technology |
52-Week High | $87.26 | $140.94 |
52-Week Low | $54.76 | $33.62 |
Typical Hold Time | 19 Days | 116 Days |
Enterprise Value | $8.60B | $618.77B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Intel (INTC) trades at $107.08, down 4.82% today but maintains a bullish technical outlook with strong 2026 performance. The stock has surged over 220% year-to-date, driven by AI momentum and foundry growth. Recent earnings beats and High-NA chipmaking progress signal operational improvement, though negative profitability metrics and high valuations present challenges. Technical indicators show bullish momentum with key support at $109.
Intel's turnaround story shows promise with foundry revenue growth and government support, but faces execution risks against dominant competitors. The stock trades near analyst consensus target of $111.72, offering modest upside potential. Key risks include competitive pressures, margin challenges, and high debt levels that could limit near-term shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
